The Economic Burden of Illness for Patients with Idiopathic Pulmonary Fibrosis Utilizing Treatment Cohorts: A US Retrospective Claims Study
Author(s)
Tanzira Zaman, M.D.1, Saloni Shah, MBA2, Geetanjan Singh Ahluwalia, PGPM3, Gary Palmer, MBBCh, MBA4, Greg Cosgrove, M.D., FCCP4, Nazim Haider, B.E, MBA4, Tejaswini Kulkarni, M.D.,MPH,FCCP5;
1Cedars-Sinai Medical Center, Director of Interstitial Lung Diseases Program, Los Angeles, CA, USA, 2Trinity Life Sciences, Waltham, MA, USA, 3Trinity Life Sciences, Gurugram, Haryana, India, 4Pliant Therapeutics, South San Francisco, CA, USA, 5The University of Alabama at Birmingham, Division of Pulmonary, Allergy and Critical Care Medicine, Birmingham, AL, USA
1Cedars-Sinai Medical Center, Director of Interstitial Lung Diseases Program, Los Angeles, CA, USA, 2Trinity Life Sciences, Waltham, MA, USA, 3Trinity Life Sciences, Gurugram, Haryana, India, 4Pliant Therapeutics, South San Francisco, CA, USA, 5The University of Alabama at Birmingham, Division of Pulmonary, Allergy and Critical Care Medicine, Birmingham, AL, USA
Presentation Documents
OBJECTIVES: Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive disease associated with high morbidity and mortality. This study aimed to understand burden of illness (BOI) and impact of treatment dosage and adherence on healthcare resource utilization (HCRU).
METHODS: A retrospective, descriptive claims analysis was conducted using Komodo Healthcare Map™ cost of care data between 1st January 2019-31st December 2023. Patients were included in the study at start of specific dosage of nintedanib or IPF diagnosis in the study period with 12-months of continuous enrollment pre-/post-index date. Descriptive analyses were conducted in the post index period across four comparator cohorts: nintedanib 100mg BID, nintedanib 150mg BID, nintedanib discontinued for 12-months, and untreated with any IPF therapy.
RESULTS: We identified 10,877 patients with IPF meeting study criteria, 10% were treated with nintedanib 150mg, 5% with nintedanib 100mg, 8% were nintedanib discontinued (either dose) for 12 months, and a vast majority (79%) were untreated with any IPF therapy. A higher proportion of the 12-month discontinued/untreated patients were hospitalized compared to those who are actively treated with nintedanib 100/150mg (35% & 31% vs 14% & 16%). A higher proportion of 12-month treatment discontinued patients underwent lung biopsies compared to nintedanib 150/100mg (38%, 26%, 25% respectively) and received higher rates of oxygen support (69%, 60%, 59% respectively) suggesting that patients who discontinued nintedanib required ongoing supportive care.
CONCLUSIONS: In this real-world cohort, a large proportion of patients diagnosed with IPF remained untreated despite known efficacy of IPF therapy in reducing the rate of decline in lung function. We further observed a high rate of oxygen therapy and hospitalization among patients discontinuing treatment, highlighting a gap in the care paradigm. Further research is needed to understand this treatment gap, despite high BOI and an increasing need for medical support in patients with IPF.
METHODS: A retrospective, descriptive claims analysis was conducted using Komodo Healthcare Map™ cost of care data between 1st January 2019-31st December 2023. Patients were included in the study at start of specific dosage of nintedanib or IPF diagnosis in the study period with 12-months of continuous enrollment pre-/post-index date. Descriptive analyses were conducted in the post index period across four comparator cohorts: nintedanib 100mg BID, nintedanib 150mg BID, nintedanib discontinued for 12-months, and untreated with any IPF therapy.
RESULTS: We identified 10,877 patients with IPF meeting study criteria, 10% were treated with nintedanib 150mg, 5% with nintedanib 100mg, 8% were nintedanib discontinued (either dose) for 12 months, and a vast majority (79%) were untreated with any IPF therapy. A higher proportion of the 12-month discontinued/untreated patients were hospitalized compared to those who are actively treated with nintedanib 100/150mg (35% & 31% vs 14% & 16%). A higher proportion of 12-month treatment discontinued patients underwent lung biopsies compared to nintedanib 150/100mg (38%, 26%, 25% respectively) and received higher rates of oxygen support (69%, 60%, 59% respectively) suggesting that patients who discontinued nintedanib required ongoing supportive care.
CONCLUSIONS: In this real-world cohort, a large proportion of patients diagnosed with IPF remained untreated despite known efficacy of IPF therapy in reducing the rate of decline in lung function. We further observed a high rate of oxygen therapy and hospitalization among patients discontinuing treatment, highlighting a gap in the care paradigm. Further research is needed to understand this treatment gap, despite high BOI and an increasing need for medical support in patients with IPF.
Conference/Value in Health Info
2025-05, ISPOR 2025, Montréal, Quebec, CA
Value in Health, Volume 28, Issue S1
Code
RWD81
Topic
Real World Data & Information Systems
Topic Subcategory
Health & Insurance Records Systems
Disease
SDC: Respiratory-Related Disorders (Allergy, Asthma, Smoking, Other Respiratory)